WO2016166418A3 - Modèle in vitro d'une inflammation chronique - Google Patents

Modèle in vitro d'une inflammation chronique Download PDF

Info

Publication number
WO2016166418A3
WO2016166418A3 PCT/FI2016/050245 FI2016050245W WO2016166418A3 WO 2016166418 A3 WO2016166418 A3 WO 2016166418A3 FI 2016050245 W FI2016050245 W FI 2016050245W WO 2016166418 A3 WO2016166418 A3 WO 2016166418A3
Authority
WO
WIPO (PCT)
Prior art keywords
chronic inflammation
vitro model
studies
model
vitro
Prior art date
Application number
PCT/FI2016/050245
Other languages
English (en)
Other versions
WO2016166418A2 (fr
Inventor
Tuula Heinonen
Jertta-Riina Sarkanen
Timo Ylikomi
Outi HUTTALA
Original Assignee
Tampereen Yliopisto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tampereen Yliopisto filed Critical Tampereen Yliopisto
Publication of WO2016166418A2 publication Critical patent/WO2016166418A2/fr
Publication of WO2016166418A3 publication Critical patent/WO2016166418A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1305—Adipocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un modèle in vitro d'une inflammation chronique destiné à être utilisé par exemple dans des études pharmacologiques et toxicologiques et dans des études sur le développement du diabète de type 2 à inflammation chronique, et en tant que modèle général en recherche fondamentale et appliquée.
PCT/FI2016/050245 2015-04-13 2016-04-13 Modèle in vitro d'une inflammation chronique WO2016166418A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20155270 2015-04-13
FI20155270 2015-04-13

Publications (2)

Publication Number Publication Date
WO2016166418A2 WO2016166418A2 (fr) 2016-10-20
WO2016166418A3 true WO2016166418A3 (fr) 2017-01-12

Family

ID=55808619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2016/050245 WO2016166418A2 (fr) 2015-04-13 2016-04-13 Modèle in vitro d'une inflammation chronique

Country Status (1)

Country Link
WO (1) WO2016166418A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044418A2 (fr) * 2005-10-06 2007-04-19 Moscatello David K Milieux de culture cellulaire, kits et procédés d’utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044418A2 (fr) * 2005-10-06 2007-04-19 Moscatello David K Milieux de culture cellulaire, kits et procédés d’utilisation

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ADRIAN C.H. TING ET AL: "The adipogenic potential of various extracellular matrices under the influence of an angiogenic growth factor combination in a mouse tissue engineering chamber", ACTA BIOMATERIALIA, vol. 10, no. 5, 1 December 2013 (2013-12-01), AMSTERDAM, NL, pages 1907 - 1918, XP055321393, ISSN: 1742-7061, DOI: 10.1016/j.actbio.2013.11.019 *
ALVI SAIRAH ET AL: "Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes", LEUKEMIA RESEARCH, vol. 25, no. 11, November 2001 (2001-11-01), pages 941 - 954, XP002760392, ISSN: 0145-2126 *
CHUA K H ET AL: "Effects of serum reduction and VEGF supplementation on angiogenic potential of human adipose stromal cells in vitro", CELL PROLIFERATION, vol. 46, no. 3, June 2013 (2013-06-01), pages 300 - 311, XP002764494 *
LEQUEUX C ET AL: "Optimization of a culture medium for the differentiation of preadipocytes into adipocytes in a monolayer", BIO-MEDICAL MATERIALS AND ENGINEERING, vol. 19, no. 4-5, 2009, pages 283 - 291, XP009192501 *
NAKARAI HIDEO ET AL: "Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: Potential link with metabolic complications", INNATE IMMUNITY, SAGE PUBLICATIONS LTD, vol. 18, no. 1, 1 February 2012 (2012-02-01), pages 164 - 170, XP009191118, ISSN: 1753-4259 *
NISHIO MIWAKO ET AL: "Differentiation of human pluripotent stem cells into highly functional classical brown adipocytes", METHODS IN ENZYMOLOGY, ACADEM. PRESS, USA, vol. 537, 1 January 2014 (2014-01-01), pages 177 - 197, XP009191114, ISSN: 1557-7988, DOI: 10.1016/B978-0-12-411619-1.00010-0 *
OUTI HUTTALA ET AL: "Human vascular model with defined stimulation medium - a characterization study", ALTEX, 2 March 2015 (2015-03-02), XP055292329, Retrieved from the Internet <URL:http://www.altex.ch/resources/altex_2015_2_125_136_Huttala4f.pdf> [retrieved on 20160729], DOI: 10.14573/altex.1411271 *
PENG ZHANGSONG ET AL: "Tissue Engineering Chamber Promotes Adipose Tissue Regeneration in Adipose Tissue Engineering Models Through Induced Aseptic Inflammation", TISSUE ENGINEERING PART C-METHODS, vol. 20, no. 11, November 2014 (2014-11-01), pages 875 - 885, XP002760393 *
SARKANEN JERTTA-RIINA ET AL: "Human adipose tissue extract induces angiogenesis and adipogenesis in vitro.", TISSUE ENGINEERING. PART A JAN 2012, vol. 18, no. 1-2, January 2012 (2012-01-01), pages 17 - 25, XP002760395, ISSN: 1937-335X *
SPENCER MICHAEL ET AL: "Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation", AMERICAN JOURNAL OF PHYSIOLOGY - ENDOCRINOLOGY AND METABOLISM, vol. 299, no. 6, December 2010 (2010-12-01), pages E1016 - E1027, XP002760391 *
VUORENPAA HANNA ET AL: "Novel in vitro cardiovascular constructs composed of vascular-like networks and cardiomyocytes", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL, vol. 50, no. 4, April 2014 (2014-04-01), pages 275 - 286, XP002760394 *

Also Published As

Publication number Publication date
WO2016166418A2 (fr) 2016-10-20

Similar Documents

Publication Publication Date Title
WO2014206561A8 (fr) Structures d&#39;anticorps
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
WO2015082046A3 (fr) Oxépines substituées
EP3040195A4 (fr) Structure en sandwich et article moulé intégré la mettant en oeuvre, ainsi que des procédés de production associés
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
EP3073171A4 (fr) Film d&#39;isolation thermique et structure de film d&#39;isolation thermique
PL2984076T3 (pl) Estry i etery 2,5-tetrahydrofuranu jako plastyfikatory
EP2958926A4 (fr) Composé épidithiodioxopipérazine ou ses dérivés, et leur utilisation
WO2015058132A3 (fr) Anticorps anti-rspo et leurs méthodes d&#39;utilisation
EP3083555A4 (fr) Procédés de diazotisation de 2,5 dichloroanilines
EP3113627A4 (fr) Composition de succédané de sucre à faible teneur en calories et procédés de fabrication de celle-ci
EP3344339A4 (fr) Molécules présentant une utilité en tant que pesticides, et intermédiaires, compositions et procédés associés
SG11201600726QA (en) 1,3-disubstituted cyclopentane derivatives
GB2502390B (en) Novel Ni complex and its derivatives, producing method, and the use thereof as antioxidant
EP3344599A4 (fr) Molécules présentant une utilité en tant que pesticide, et leurs intermédiaires, compositions et procédés
EP3347341B8 (fr) Molécules présentant une utilité en tant que pesticides, ainsi qu&#39;intermédiaires, compositions, et procédés associés
MX2015017638A (es) Polioles que contienen tanino, su producción y su uso.
EP3344600A4 (fr) Molécules présentant une utilité en tant que pesticide, et leurs intermédiaires, compositions et procédés
EP3065726A4 (fr) Analogues de créatine et leur utilisation
EP3078671A4 (fr) Dérivé de gemcitabine, composition contenant le dérivé et utilisation pharmaceutique du dérivé
EP3038631A4 (fr) Compositions anti-inflammatoires, méthodes et utilisations correspondantes
JP2015529327A5 (fr)
EP3344040A4 (fr) Molécules à usage pesticide, et intermédiaires, compositions et procédés associés
HK1215863A1 (zh) 光交聯的透明質酸衍生物及其製備方法和應用
WO2015044434A3 (fr) Fluoro-9-méthyl-β-carboline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16718385

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16718385

Country of ref document: EP

Kind code of ref document: A2